We partnered with Volition to offer Nu.Q® Discover service and expand our liquid biopsy epigenomic profiling in the chromatin space to accelerate translational research and clinical development.
PRC2 is a histone methyltransferase complex that is often dysregulated in cancer. Small-molecule inhibitors (Epidrugs) targeting its subunits have entered clinical trials and shown promising activity, as these agents reduce H3K27me3 levels and reprogram gene expression [1].
The Nu.Q® Discover assays have been used in liquid biopsy to precisely measure the direct and dynamic effect of PRC2 inhibitors on global H3K27me3 levels, showing [2]:
Higher PRC2 inhibition via increasing epidrug dose as shown by decreasing H3K27me3-nucleosome levels.
Increased epidrug efficacy with prolonged administration demonstrated by significant decrease of H3K27me3-nucleosome levels over treatment time.
Efficient target selectivity of the epidrug as per the significant decrease in H3K27me3-nucleosome levels following administration exhibited only in tumor-bearing mice.
*Nu.Q® is a registered trademark of VolitionRx Limited and its subsidiaries.
RERERENCES:
[1] Kim et al., “Epigenetic therapy targeting histone methylation in cancer” Experimental & Molecular Medicine, 2020, 52, 227–237.
[2] Daemen A., et al., Abstract 2791, Cancer Res, 2023.
“We look forward to working with the Hologic Diagenode team to strengthen Nu.Q® Discover Service's unique positioning between liquid biopsy, epigenomics, and drug development.”
– Jasmine Kway, Chief Executive Officer, Volition Singapore
